Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Two Big Biotech Firms Cut Jobs
by Lisa M. Jarvis
November 17, 2008
| A version of this story appeared in
Volume 86, Issue 46
Amylin Pharmaceuticals is slashing 25% of its workforce, or 340 employees, as it attempts to turn a profit in 2009. The San Diego-based company says the restructuring move will save it more than $100 million in operating expenses next year and even more in 2010. Sales of Amylin's two diabetes treatments, Byetta and Symlin, grew 15% to $580 million in the first nine months of the year, but the firm has yet to show investors a return. Separately, Exelixis will trim 10% of its staff, or 78 employees, to better balance the cash it is bringing in with what it spends on research.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter